JHU–Pfizer CTI

JHU–Pfizer CTI


JHU–Pfizer CTI HOME | CTI Proposal Process | JHU and Pfizer CTI Joint Steering Committee | Frequently Asked Questions

 

Overview

The Johns Hopkins University has teamed up with Pfizer’s Centers for Therapeutic Innovation (CTI), a program designed to help bridge the gap between early scientific discovery and its translation into new medicines through public-private collaborations. As a result of this collaboration, The Johns Hopkins University researchers have the opportunity to work with Pfizer on research projects pursuing scientific and medical advances.

The goal of this new collaboration is to identify large- and small-molecule compounds with activity in a pathway or target of interest to a Johns Hopkins researcher and to CTI/Pfizer. Together, the collaborators will work to advance these programs with the goal of entering early stage clinical trials.

Participants in the CTI network include 30 academic institutions, six patient foundations, the NIH and now The Johns Hopkins University.

Click here to learn more about the CTI’s Therapeutic Areas of Interest for Spring 2019.

How CTI Works

Projects appropriate for this collaboration will have identified disease-related pathways or mechanisms as potential therapeutic targets. The CTI collaboration enables The Johns Hopkins University investigators to advance research projects in the lab, with the goal of moving the project into the clinic by providing access to Pfizer’s drug development expertise. A research program with CTI includes funding for the research, access to Pfizer’s drug development expertise, as well as publishing rights.

A joint The Johns Hopkins University and Pfizer CTI steering committee will govern the collaborative effort, and it will be responsible for selecting and making decisions about the progress of each research program. The committee will consider funding research in various stages, from early research project concepts to those with a therapeutic candidate developed.

This new research collaboration will enable Johns Hopkins scientists to move novel disease targets into therapeutic development using industry support and expertise. For Pfizer, the collaboration will provide access to the Johns Hopkins University’s research expertise. Most importantly, patients have the potential to benefit from two of the world’s premier research organizations working together with the common goal of developing treatments faster.

CTI Proposal Process

The CTI program has two calls for proposals each year. The next scheduled call will close on April 29, 2019. Click here to learn more about the proposal process.

 

 

 

  • NEXT PRE-PROPOSAL DEADLINE
  • Submission to Johns Hopkins Technology Ventures (JHTV, Sean Evans) begins: Tuesday, March 26, 2019
  • Deadline for submission to Johns Hopkins Technology Ventures (JHTV, Sean Evans): Monday, April 29, 2019
  • Deadline for JHTV to submit to CTI: Monday, May 6, 2019